1 reports of this reaction
50.0% of all DIMETHICONE, OCTINOXATE, OCTISALATE, OXYBENZONE reports
#1 most reported adverse reaction
BLISTER is the #1 most commonly reported adverse reaction for DIMETHICONE, OCTINOXATE, OCTISALATE, OXYBENZONE, manufactured by The Mentholatum Company. There are 1 FDA adverse event reports linking DIMETHICONE, OCTINOXATE, OCTISALATE, OXYBENZONE to BLISTER. This represents approximately 50.0% of all 2 adverse event reports for this drug.
Patients taking DIMETHICONE, OCTINOXATE, OCTISALATE, OXYBENZONE who experience blister should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLISTER is a frequently reported adverse event for DIMETHICONE, OCTINOXATE, OCTISALATE, OXYBENZONE, accounting for a significant proportion of all reports.
In addition to blister, the following adverse reactions have been reported for DIMETHICONE, OCTINOXATE, OCTISALATE, OXYBENZONE:
The following drugs have also been linked to blister in FDA adverse event reports:
BLISTER has been reported as an adverse event in 1 FDA reports for DIMETHICONE, OCTINOXATE, OCTISALATE, OXYBENZONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLISTER accounts for approximately 50.0% of all adverse event reports for DIMETHICONE, OCTINOXATE, OCTISALATE, OXYBENZONE, making it one of the most commonly reported side effect.
If you experience blister while taking DIMETHICONE, OCTINOXATE, OCTISALATE, OXYBENZONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.